X

Trial Profile

A longitudinal study analysing antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tozinameran (Primary)
Indications SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Acronyms CONsort-19

Most Recent Events

15 Oct 2021 Results (n=396) assessing the incidence of positive SARS-CoV-2 real-time reverse-transcriptase polymerase chain reaction (RT-qPCR) results according to the vaccination status published in the Allergy
29 Jul 2021 New trial record
19 Jul 2021 Results published in the Allergy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com